Damora Therapeutics (DMRA) Gains from Sales and Divestitures (2024 - 2026)
Damora Therapeutics posted quarterly Gains from Sales and Divestitures of $5292.0 for Q1 2026, up 2.8% year-on-year from $5148.0 in Q1 2025, and down 32.15% on a QoQ basis from $7800.0 in Q4 2025.
Damora Therapeutics (DMRA) has 3 years of Gains from Sales and Divestitures data on file, last reported at $5292.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 2.8% year-over-year to $5292.0; the trailing twelve-month figure through Mar 2026 stood at $5292.0 (up 2.8% YoY), and the FY2025 full-year result was $7800.0, up 10.64% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $5292.0, down from $7800.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $17499.0 in Q2 2024 and bottomed at $5148.0 in Q1 2025.
- The 3-year median for Gains from Sales and Divestitures is $6939.0 (2024), against an average of $7820.6.
- Peak annual rise in Gains from Sales and Divestitures reached 14.24% in 2025, while the deepest fall reached 70.58% in 2025.
- A 3-year view of Gains from Sales and Divestitures shows it stood at $7050.0 in 2024, then grew by 10.64% to $7800.0 in 2025, then slumped by 32.15% to $5292.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $5292.0 (Q1 2026), $7800.0 (Q4 2025), and $7800.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,292.00 |
| Mar 31, 2026 | 5,292.00 |
| Dec 31, 2025 | 7,800.00 |
| Dec 31, 2025 | 7,800.00 |
| Sep 30, 2025 | 7,800.00 |
| Sep 30, 2025 | 7,800.00 |
| Jun 30, 2025 | 5,148.00 |
| Jun 30, 2025 | 5,148.00 |
| Mar 31, 2025 | 5,148.00 |
| Mar 31, 2025 | 5,148.00 |
| Dec 31, 2024 | 7,050.00 |
| Dec 31, 2024 | 7,050.00 |
| Sep 30, 2024 | 6,828.00 |
| Sep 30, 2024 | 6,828.00 |
| Jun 30, 2024 | 17,499.00 |
| Jun 30, 2024 | 17,499.00 |